Nofetumomab merpentan

Nofetumomab Merpentan (also known as Verluma) is a monoclonal antibody designed for the treatment of various types of cancer. It was developed by Pharmacia and later acquired by Novartis.

History

Nofetumomab Merpentan was initially developed by Pharmacia, a Swedish pharmaceutical company. After the acquisition of Pharmacia by Pfizer in 2003, the development rights for Nofetumomab Merpentan were transferred to Novartis.

Mechanism of Action

Nofetumomab Merpentan is a monoclonal antibody that targets the carcinoembryonic antigen (CEA), a protein often overexpressed in cancer cells. By binding to this antigen, Nofetumomab Merpentan can help the immune system recognize and destroy cancer cells.

Clinical Trials

Several clinical trials have been conducted to evaluate the efficacy and safety of Nofetumomab Merpentan in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, and breast cancer.

Side Effects

Like all medications, Nofetumomab Merpentan can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and fatigue.

Current Status

As of 2021, Nofetumomab Merpentan is not currently approved for use in any country. However, research is ongoing to further evaluate its potential as a cancer treatment.

See Also

• Monoclonal antibodies
• Carcinoembryonic antigen
• Pharmaceutical industry